{
  "docId": "019de076-6120-7265-9083-1f4de3ff0bf7",
  "docSlug": "b6cd6d5e2a349d701bc6db22946ed621",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 52,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a side-by-side comparison layout to distinguish between the dose escalation (Phase 1) and the registrational intent (Phase 2) study designs.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-6120-7265-9083-1f4de3ff0bf7/15",
  "deckHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7",
  "deckJsonHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7.json",
  "deckAnchorHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.5,
        "y": 0.38
      },
      "kind": "list",
      "text": "Global trial for TKI-naïve/treated patients; Multi-cohort design; NVL-520 at 100 mg QD",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d9a1066-9d2a-4de4-b3b2-f821090be0da",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.08,
        "y": 0.33
      },
      "kind": "list",
      "text": "Advanced solid tumors harboring ROS1 fusions; ≥ 1 prior ROS1 TKI; No limit to prior therapies; Excluded concurrent drivers; Evaluable disease allowed",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7dca7fd9-d240-40f6-97eb-c0438be2bcf7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.08,
        "y": 0.26
      },
      "kind": "paragraph",
      "text": "Phase 1: DOSE ESCALATION IN HEAVILY PRE-TREATED ROS1-POSITIVE PATIENTS",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0437098c-5e73-4933-a8ff-b4a5fb2fe2c7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.5,
        "y": 0.26
      },
      "kind": "paragraph",
      "text": "Phase 2: STATUS: OPEN AND ENROLLING",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "47312f49-50cd-403b-81d3-214ef3418fcf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.07,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "CNS, central nervous system; DLTs, dose-limiting toxicities; MTD, maximum tolerated dose; NSCLC, non-small cell lung cancer; PK, pharmacokinetics; RP2D, recommended phase 2 dose; ROS1+, ROS1-positive; TKI, tyrosine kinase inhibitor; a Patients with baseline concurrent oncogenic drivers identified on subsequent testing and without measurable disease are excluded from efficacy evaluation per prespecified protocol analysis plan.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "72b2f878-ecd2-4e7f-9123-d214ba84529a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "title",
      "text": "ARROS-1: First-in-Human Phase 1/2 Clinical Trial of NVL-520 in Advanced ROS1-Positive NSCLC and Other Solid Tumors (NCT05118789)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5fec3cfe-57dd-44f0-9b5d-6c7c5d097b67",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "SCQA Framework",
      "slug": "scqa-framework",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "f887bca6-ed08-40b2-8a50-b1b12b8e25bf",
      "evidence": "The slide presents a clear structure with a title, bullet points, and a specific trial description, setting the scene (S), providing context (C), and questioning the audience (Q) about the trial's objectives and design.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 24,
      "from": 13,
      "beatId": "8a9285c3-c673-4982-a754-e50ef65833d8",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "Slides 13-24: Preclinical and clinical trial results for NVL-520.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}